Myocardial Infarction – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Myocardial Infarction – Pipeline Review, H2 2019’, provides an overview of the Myocardial Infarction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction

– The report reviews pipeline therapeutics for Myocardial Infarction by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Myocardial Infarction therapeutics and enlists all their major and minor projects

– The report assesses Myocardial Infarction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Myocardial Infarction”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Actinogen Medical Ltd

Angion Biomedica Corp

Ankasa Regenerative Therapeutics Inc

Aposcience AG

Applied Therapeutics Inc

Aprogen Inc

APT Therapeutics Inc

AstraZeneca Plc

Athera Biotechnologies AB

Athersys Inc

Axolo Pharma Inc

Beijing Northland Biotech Co Ltd

Bharat Biotech Ltd

BioCardia Inc

Cadila Healthcare Ltd

CardioCreate Inc

Cardiol Therapeutics Inc

Cardior Pharmaceuticals GmbH

CeleCor Therapeutics Inc

Celixir Ltd

CellProthera SAS

CFM Pharma Holding BV

Cynata Therapeutics Ltd

DepYmed Inc

Diffusion Pharmaceuticals Inc

Domainex Ltd

Ever Supreme Bio Technology Co Ltd

Evotec SE

EyeGene Inc

Faraday Pharmaceuticals Inc

General Regeneratives Shanghai Ltd

Generium

GNT Pharma Co Ltd

Hemostemix Inc

Honya Medical Inc

HUYA Bioscience International LLC

Idorsia Pharmaceutical Ltd

iHeart Japan Corp

InCarda Therapeutics Inc

Innolife Co Ltd

Inotrem SA

IPS Heart Inc

K-Stemcell Co Ltd

Kine Sciences

Lee’s Pharmaceutical Holdings Ltd

LTT Bio-Pharma Co Ltd

MandalMed Inc

Mesoblast Ltd

MIFCOR Inc

MimeTech Srl

Mirae Cell Bio Co Ltd

New World Laboratories Inc

Novartis AG

NuvOx Pharma LLC

OMEICOS Therapeutics GmbH

OP2 Drugs SAS

Opsona Therapeutics Ltd

OtiTopic LLC

Pharmahungary Group

Primary Peptides Inc

Quark Pharmaceuticals Inc

Qurgen Inc

Reata Pharmaceuticals Inc

Recardio GmbH

RegeneRx Biopharmaceuticals Inc

Reliance Life Sciences Pvt Ltd

ResoTher Pharma ApS

Rubicon Biotechnology Inc

Sentan Pharma Inc

Serpin Pharma LLC

Silver Creek Pharmaceuticals Inc

SmartPharm Therapeutics Inc

Sorrento Therapeutics Inc

T&R Biofab Co Ltd

TaiGen Biotechnology Co Ltd

Takeda Pharmaceutical Co Ltd

Techfields Pharma Co Ltd

Thrombolytic Science International LLC

Translational Sciences Inc

Vaxil Bio Therapeutics Ltd

XBiotech Inc

Xcelthera INC

Yichang Humanwell Pharmaceutical Co Ltd

Yuyu Pharma Inc”

Table of Contents

Table of Contents

Introduction

Myocardial Infarction Overview

Myocardial Infarction Therapeutics Development

Myocardial Infarction Therapeutics Assessment

Myocardial Infarction Companies Involved in Therapeutics Development

Myocardial Infarction Drug Profiles

Myocardial Infarction Dormant Projects

Myocardial Infarction Discontinued Products

Myocardial Infarction Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Myocardial Infarction, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Myocardial Infarction – Pipeline by Actinogen Medical Ltd, H2 2019

Myocardial Infarction – Pipeline by Angion Biomedica Corp, H2 2019

Myocardial Infarction – Pipeline by Ankasa Regenerative Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by Aposcience AG, H2 2019

Myocardial Infarction – Pipeline by Applied Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by Aprogen Inc, H2 2019

Myocardial Infarction – Pipeline by APT Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by AstraZeneca Plc, H2 2019

Myocardial Infarction – Pipeline by Athera Biotechnologies AB, H2 2019

Myocardial Infarction – Pipeline by Athersys Inc, H2 2019

Myocardial Infarction – Pipeline by Axolo Pharma Inc, H2 2019

Myocardial Infarction – Pipeline by Beijing Northland Biotech Co Ltd, H2 2019

Myocardial Infarction – Pipeline by Bharat Biotech Ltd, H2 2019

Myocardial Infarction – Pipeline by BioCardia Inc, H2 2019

Myocardial Infarction – Pipeline by Cadila Healthcare Ltd, H2 2019

Myocardial Infarction – Pipeline by CardioCreate Inc, H2 2019

Myocardial Infarction – Pipeline by Cardiol Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by Cardior Pharmaceuticals GmbH, H2 2019

Myocardial Infarction – Pipeline by CeleCor Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by Celixir Ltd, H2 2019

Myocardial Infarction – Pipeline by CellProthera SAS, H2 2019

Myocardial Infarction – Pipeline by CFM Pharma Holding BV, H2 2019

Myocardial Infarction – Pipeline by Cynata Therapeutics Ltd, H2 2019

Myocardial Infarction – Pipeline by DepYmed Inc, H2 2019

Myocardial Infarction – Pipeline by Diffusion Pharmaceuticals Inc, H2 2019

Myocardial Infarction – Pipeline by Domainex Ltd, H2 2019

Myocardial Infarction – Pipeline by Ever Supreme Bio Technology Co Ltd, H2 2019

Myocardial Infarction – Pipeline by Evotec SE, H2 2019

Myocardial Infarction – Pipeline by EyeGene Inc, H2 2019

Myocardial Infarction – Pipeline by Faraday Pharmaceuticals Inc, H2 2019

Myocardial Infarction – Pipeline by General Regeneratives Shanghai Ltd, H2 2019

Myocardial Infarction – Pipeline by Generium, H2 2019

Myocardial Infarction – Pipeline by GNT Pharma Co Ltd, H2 2019

Myocardial Infarction – Pipeline by Hemostemix Inc, H2 2019

Myocardial Infarction – Pipeline by Honya Medical Inc, H2 2019

Myocardial Infarction – Pipeline by HUYA Bioscience International LLC, H2 2019

Myocardial Infarction – Pipeline by Idorsia Pharmaceutical Ltd, H2 2019

Myocardial Infarction – Pipeline by iHeart Japan Corp, H2 2019

Myocardial Infarction – Pipeline by InCarda Therapeutics Inc, H2 2019

Myocardial Infarction – Pipeline by Innolife Co Ltd, H2 2019

Myocardial Infarction – Pipeline by Inotrem SA, H2 2019

Myocardial Infarction – Pipeline by IPS Heart Inc, H2 2019

Myocardial Infarction – Pipeline by K-Stemcell Co Ltd, H2 2019

Myocardial Infarction – Pipeline by Kine Sciences, H2 2019

Myocardial Infarction – Pipeline by Lee’s Pharmaceutical Holdings Ltd, H2 2019

Myocardial Infarction – Pipeline by LTT Bio-Pharma Co Ltd, H2 2019

Myocardial Infarction – Pipeline by MandalMed Inc, H2 2019

Myocardial Infarction – Pipeline by Mesoblast Ltd, H2 2019

Myocardial Infarction – Pipeline by MIFCOR Inc, H2 2019

Myocardial Infarction – Pipeline by MimeTech Srl, H2 2019

Myocardial Infarction – Pipeline by Mirae Cell Bio Co Ltd, H2 2019

Myocardial Infarction – Pipeline by New World Laboratories Inc, H2 2019

Myocardial Infarction – Pipeline by Novartis AG, H2 2019

Myocardial Infarction – Pipeline by NuvOx Pharma LLC, H2 2019

Myocardial Infarction – Pipeline by OMEICOS Therapeutics GmbH, H2 2019

Myocardial Infarction – Pipeline by OP2 Drugs SAS, H2 2019

Myocardial Infarction – Pipeline by Opsona Therapeutics Ltd, H2 2019

Myocardial Infarction – Pipeline by OtiTopic LLC, H2 2019

Myocardial Infarction – Pipeline by Pharmahungary Group, H2 2019

Myocardial Infarction – Pipeline by Primary Peptides Inc, H2 2019

Myocardial Infarction – Pipeline by Quark Pharmaceuticals Inc, H2 2019

Myocardial Infarction – Pipeline by Qurgen Inc, H2 2019

Myocardial Infarction – Pipeline by Reata Pharmaceuticals Inc, H2 2019

Myocardial Infarction – Pipeline by Recardio GmbH, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Myocardial Infarction, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared